What BMI do you need for Wegovy or Mounjaro?

BMI criteria for Wegovy and Mounjaro

For adults starting obesity treatment in the UK, prescribing generally follows NICE-aligned thresholds:

• BMI 30 or higher (obesity), or
• BMI 27 or higher (overweight) with at least one weight-related health condition

Weight-related conditions commonly include:

• Prediabetes or type 2 diabetes
• High blood pressure (hypertension)
• High cholesterol (dyslipidaemia)
• Obstructive sleep apnoea
• Established cardiovascular disease

These cut-offs apply to both once-weekly semaglutide (Wegovy) and once-weekly tirzepatide (Mounjaro) for weight management when licensed criteria are met. BMI alone never guarantees a prescription: contraindications, pregnancy, certain cancers, pancreatitis history, and other factors matter too.

Is eligibility different for Wegovy vs Mounjaro?

On BMI, usually no. The difference between them is mechanism, dosing, side effects, and individual response, not a separate BMI ladder. Compare options in Mounjaro vs Wegovy and read our doctor's guide to Wegovy or what is tirzepatide (Mounjaro) for treatment-specific detail.

Switching between medicines, restarting after a break, or continuing at maintenance dose all need a fresh clinical review; see restarting treatment after a break and maintenance support.

BMI for Wegovy Pill, Nevolat, Mysimba, and orlistat

Not everyone starts on weekly injections. Other PrivateDoc options include:

• Wegovy Pill (oral semaglutide, where licensed): broadly similar obesity BMI principles to injectable semaglutide
• Nevolat (daily liraglutide): typically BMI 30+ or 27+ with weight-related comorbidity when prescribed for weight management
• Mysimba and orlistat: separate licensing rules; often BMI 30+ or 27+ with a weight-related comorbidity

See all weight loss treatments and how to get prescription weight loss medication online in the UK for the wider pathway.

Why your BMI matters (and its limits)

BMI estimates body fat from height and weight. UK regulators and NICE use it as a practical screening tool for obesity medicines. It does not measure muscle mass or fat distribution, so athletes and very muscular people may have a high BMI without high body fat.

That is why clinical assessment always goes beyond a calculator result.

Lower thresholds for some ethnic backgrounds

NICE notes that people from some ethnic groups may face equivalent metabolic risk at a lower BMI. Clinicians may apply adjusted cut-offs (often around 2.5 BMI points lower) for backgrounds including:

• South Asian
• Chinese
• Middle Eastern
• Black African
• African-Caribbean

PrivateDoc clinicians apply this context during consultation so assessment stays fair and personalised.

How PrivateDoc checks eligibility

Meeting BMI criteria is step one. Our programme also includes:

• Review by UK-registered prescribers
• Virtual check-ins and progress monitoring
• Diet and lifestyle resources, including our SIRTfood dietary guide
• Dose titration support for GLP-1 medicines; see Wegovy dose schedule and Mounjaro dose schedule

Start a confidential online consultation. We will review your BMI, health history, and goals before advising whether Wegovy, Mounjaro, or another treatment fits.

Related guides

• Mounjaro vs Wegovy
• Prescription weight loss medication online (UK)
• Wegovy dose schedule
• Mounjaro dose schedule
• Patient stories
• All weight loss treatments